1Q FY2014(Fiscal Year Ending March 31, 2015)

Financial Results Presentation
Eisai Co., Ltd.

August 1, 2014

Safe Harbor Statement

1•

Materials and information provided during this presentation may contain so-called “forwardlooking statements.” These statements are based on current expectations, forecasts andassumptions that are subject to risks and uncertainties which could cause actual outcomes andresults to differ materially from these statements.

•

Risks and uncertainties include general industry and market conditions, and general domestic
and international economic conditions such as interest rate and currency exchange fluctuations.
Risks and uncertainties particularly apply with respect to product-related forward-looking
statements. Product risks and uncertainties include, but are not limited to, technologicaladvances and patents attained by competitors; challenges inherent in new productdevelopment, including completion of clinical trials; claims and concerns about product safety
and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic
and foreign healthcare reforms; trends toward managed care and healthcare cost containment;
and governmental laws and regulations affecting domestic and foreign operations.

•

For any forward-looking statements the Company cannot guarantee the actual outcomes andresults.

•Also, for products that are approved, there are manufacturing and marketing risks anduncertainties, which include, but are not limited to, inability to build production capacity to meetdemand, unavailability of raw materials, and failure to gain market acceptance.

•

The Company disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or otherwise.

•This English presentation was translated from the original Japanese version. In the event of
any inconsistency between the statements in the two versions, the statements in the Japaneseversion shall prevail.

Strategic Plan of FY2014

Strategic investment for return to growth trajectory
Transformation in FY2014
1. Expansion and development of new growth drivers(4 global brands*1, 8 pipeline assets*2, Asia and strategic markets*3)
2. Business expansion responding to the needs of global market
Launch of Global Business Matrix
Improve access to medicine

3. Adoption of IFRS to increase capability in global comparison of financial status
Forecast for FY2014 Consolidated Financial Performance
Upfront investment in 1H to seek
returning to growth trajectory from 2H*4

売上収益
Revenue

下期
2H

276.0B yen

290.0B yen

49%

51%

Revenue
566.0B yen (94% YoY)
Operating 20.0B yen
営業利益Operating profit
53.0B yen (80% YoY)
38%
profitProfit for the period 35.0B yen (91% YoY)
Profit for 12.5B yen
当期利益Dividend
150 yen36%
the period*5Pharma EBIT
174.5B yen (86% YoY)
0%
2

上期
1H

33.0B yen62%
22.5B yen

64%
50%

100%

*1: Halaven, Fycompa, BELVIQ® and investigational lenvatinib *2: Halaven, Fycompa and BELVIQ®
(Investigational): lenvatinib, E2006, BAN2401, E2609 and Avatrombopag*3: Canada, Mexico, Brazil, Russia, Middle East and Australia*4: An increase in operating profit is forecast for the 2nd half of FY2014 excluding the impact of the divesture ofdevelopment and marketing lights of Dacogen to Otsuka Pharmaceutical Co., Ltd. (as of March 31, 2014), an increase in revenue is forecast for the 2nd half of FY2014*5: Pharma EBIT: Operating profit + R&D Expenses

1Q FY2014 Consolidated Statement of Income (IFRS)Revenue and operating profit are in-line level to business plan
(Billion yen, %)April – June 2013
Results

Revenue

Results

%

YoY

152.8

100.0

132.8

100.0

87

46.2

30.2

48.1

36.2

104

Gross Profit

106.6

69.8

84.7

63.8

79

R&D Expenses

37.3

24.4

29.1

21.9

78

SG&A Expenses

50.6

33.1

47.2

35.5

93

Other income &expenses

(0.2)

(0.1)

0

0.0

Operating profit

18.6

12.1

8.5

6.4

46

Profit for the period

12.3

8.1

5.7

4.3

46

Pharma EBIT*

55.8

36.5

37.6

28.3

67

Cost of Sales

3%

April – June 2014

* Pharma EBIT: Operating profit + R&D Expenses
FY2014 1Q average exchange rates: U.S. $ = 102.16 yen (+3.5% YoY), Euro = 140.06 yen (+8.6% YoY), GBP = 171.91 yen (+13.4% YoY)

Breakdown of Revenue Migration
Impact of AcipHex LOE in the U.S.
and drug price revisions in Japan(Billion yen)

+2.9

-11.6

+1.9
1,500
150

-5.4
-7.8

1,400
140

-20.0B yen
YoY

152.8
130
1,300

132.8
120
1,200

1Q2013年度
FY2013
Revenue
4-6月
売上収益

*1
Growth ofExpansion of
Impact ofグローバル
成長セグメント
米国
global brands growing segments*1
AcipHex
ブランドの拡大の伸長
アシフェックス
LOE inLOE Halaven +1.2 Asia+2.8
the U.S.
*3

 Fycompa +0.1
 BELVIQ® +0.6

Strategic markets

Drug
国内
price
薬価改定
revisionsin Japan

Others
その他の増減Including the impact ondivesture of thedevelopment andmarketing rights ofDacogen*2, etc.

+0.1

* Figures shown on breakdown of revenue migration are approximate

4*1: Excluding revenue of global brands *2: Global rights (excluding Mexico) transferred to Otsuka Pharmaceutical Co., Ltd. as of March 31, 2014
*3: Canada, Mexico, Brazil, Russia, Middle East and Australia

1Q
FY20142014年度
Revenue
4-6月
売上収益Breakdown of Operating Profit Migration
Investments aiming at rapid growth beyond FY2015
1. Expansion of global brands
5.1B yen
2. Acceleration of product creation of 8 priority pipelines*1 1.8B yen
3. Expansion in Asian and strategic markets*2
1.8B yen(Billion yen)

+2.7
+1.5

20
200

-8.7
1
2
3

10
100

-5.6
-10.1B yen
YoY

18.6

8.5
0
1Q2013年
FY2013Operating4-6月
profit営業利益

5Growth of
グローバル
global brands
ブランドの育成

Expansion of
成長セグメント
growing segments*3の拡大Halaven
Fycompa
BELVIQ®

 Asia Strategic
markets*2

Upfront
1Q FY2014
Others
将来に向けたその他の増減2014年
investment forOperating
先行投資
futuregrowth <Major factors for increase> 4-6月
profit(net
increase) Upfront payment from
（純増分）
営業利益

*Figures shown on breakdown of operating profit migration are approximate*1: Halaven, Fycompa, BELVIQ®, (Investigational):Lenvatinib, E2006, BAN2401, E2609, Avatrombopag*2: Canada, Mexico, Brazil, Russia, Middle East and Australia*3: Global rights (excluding Mexico) transferred to Otsuka Pharmaceutical Co., Ltd. as of March 31, 2014

Biogen Idec Inc.

<Major factor for decrease>Impact of AcipHex LOE in the U.S.
Drug price revisions in Japan
Divesture of the development
and marketing rights of Dacogen*4

Forecast for FY2014
Consolidated Statement of Income (IFRS)(Billion yen, %)FY2013Results

FY2014%

Forecast

%

YoY

599.5

100.0

566.0

100.0

94

194.7

32.5

200.0

35.3

103

Gross Profit

404.8

67.5

366.0

64.7

90

R&D Expenses

136.3

22.7

121.5

21.5

89

SG&A Expenses and others*1

202.1

33.7

191.5

33.8

95

Operating profit

66.4

11.1

53.0

9.4

80

Profit for the period

38.5

6.4

35.0

6.2

91

Pharma EBIT*2

202.7

33.8

174.5

30.8

86

Revenue
Cost of Sales

EPS (yen)

134.1

122.4

ROE (%)

7.6

6.7

DOE (%)

8.5

8.2

Dividends (yen)

150

150

91

*1: Selling expenses + personnel expenses + administrative and other expenses *2: Pharma EBIT: Operating profit + R&D Expenses
FY2013 average exchange rate: U.S. $ = 100.23 yen, Euro = 134.36 yen, GBP = 159.44 yen
Estimated average exchange rates for FY2014: U.S. $ = 103.00 yen, Euro = 140.00 yen, GBP = 170.00 yen

6Growth of 3 Global Brands

Transition of revenue for3 global brands

125% YoY
9.9B yen(Billion yen)

3 Global brands

7.9B yen
100
10

Halaven

5.5B yen
Fycompa50
5

BELVIQ®

0
1Q 2012年度
FY2012
Results
4-6月実績
7

1Q 2013年度
FY2013Results
4-6月実績

1Q2014年度
FY2014
Results
4-6月実績

Eisai Global Oncology Business Unit

Aim to expand patient contribution with Halavenand other oncology products

Global Halaven
1Q revenue 8.2B yen; Achieved 118% YoY
Obtained approval in 54 countries
with MBC*1 indication(as of the end of July 2014)

Revenue of Halaven

U.S.: Obtained approval for pediatric use
on May 27th
Received additional six months US market
exclusivity until October 13th, 2015
8 *1: Metastatic breast cancer *2: JPY base *3: Europe, Middle East, Africa, Russia, and Oceania
and Taiwan

6.9B yen90
9Americas: Achieved 117% YoY*2 growth in 1Q FY2014
Increased market share of 3rd line+ treatment byfocusing on patients with HER2 negative type
*3
EMEA : Achieved 129% YoY*2 growth in 1Q FY2014
Obtained approval for earlier line treatment in EU
on June 30th
Japan: Seek position as standardized treatment for 2nd line byfocusing on efficacy for patients with HER2 negative type
Asia: Launched in 8 countries*4. Maximize patient contribution
through Patient Assistance Program.

Aloxi

8.2B yen(Billion yen)

5.5B yen
60
6

330

0
2012年度1Q
1Q
FY2012

2013年度1Q
1Q FY20132014年度1Q
1Q
FY2014

Investigational Lenvatinib*5
Achieved submission in Japanon June 26th
Plan to submit in August in U.S. and EU
Initiated global launch preparation*4: Singapore, South Korea, Thailand, Hong Kong, Philippines, India, Malaysia*5: Lenvatinib is a generic name. Brand name has not been registered. Submission for radioiodine- refractory differentiated thyroid cancer

Eisai Global Neurology Business Unit

Seeking global ramp-up in FY2015 and beyond

Fycompa

BELVIQ®

Obtained approval in 39 countries
for adjunctive therapy
for partial-onset seizures

Seeking growth throughcontinued strategic investment(as of the end of July 2014)• Launched in France, the Netherlands andRussia• Obtained approval in Australia (May 2014),
seeking to launch in FY2014

Continue to increase brand awarenessthrough strategic activities in the U.S.
• Educate physicians about its novel mode ofaction through 90 sales representatives• Expanded Speaker Bureau to educate
physicians on Fycompa in order to increase thenumber of prescribers
9

(TRx)

Transition of monthly TRx(June 2013 to June 2014)

40,000

Launch of DRTV*2

Number of monthly
TRx are growing
throughprint advertisement
and DRTV*2

30,00020,000Enhance marketing activity
through 600 sales
representatives

10,0000

Jun-13
Jul-13Aug-13
Sep-13Oct-13
Nov-13
Dec-13Jan-14Feb-14Mar-14Apr-14May-14Jun-14

Expansion of approved andlaunched countries in EMEA*1*1: Europe, Middle East, Africa, Russia, and Oceania * 2: Direct Response television(Source: IMS NPA)

Present Status of
Asia and Strategic Markets
Asia
Stable growth of China, South Korea and two major products
Transition of revenue
in Asia(Billion yen)

150
15

その他
Others韓国South Korea
China
中国

South
Korea

1.7

(Billion yen)South
Korea 3.0
South
Korea 2.4

100
10

50
5

Total 13.4B yen

Total 9.6B yen

Transition of revenue for
2 major products

Total 16.3B yen
122% YoY40
40
2012年度
2014年度1Q FY2014
1Q FY2012 2013年度
1Q FY2013
4-6月実績
Results 4-6月実績
Results4-6月実績Results

Launched Chocola BB Royal
Drink through internet retailing
3.2

2.5
2.0

2
20

China 5.1

June 2014:

3.6
2.9

China 9.2

China 7.0

2012年度4-6月実績
1Q FY2012 Results
2013年度4-6月実績
1Q FY2013 Results
2014年度4-6月実績
1Q FY2014 Results
4.6

Launched OTC businessin China

0

メチコバール
Methycobal

アリセプト
Aricept

Strategic Markets

Chocola BB Royal Drink and its box
package for internet retailing*1

Accelerate business expansion toward revenue target of 6.0B yen in Russia in FY2018
Oncology area: Halaven launched in September 2013
Epilepsy area: Zonegran launched in April 2014; Fycompa launched in June 2014
Exalief*2 approved in May 2014, launch planned in FY2014
10*1: Canada, Mexico, Brazil, Russia, Middle East and Australia*2: Brand name of Zebinix in Russia

Fycompa in Russia

Achieved Major Milestones in Product Creation

Investigational
Lenvatinib

11

 Achieved submission in Japan for theindication as treatment of radioiodinerefractory differentiated thyroid cancer
in JuneHalaven Obtained approval for earlier line
treatment of MBC* in EU in June

Fycompa

 Achieved primary endpoint in phase III
study for primary generalized tonicclonic seizures in June

* Metastatic Breast Cancer

Investigational Lenvatinib

Demonstrated highly statistically significant improvement in PFS
in radioiodine-refractory differentiated thyroid cancer

Response rate

Primary Endpoint: PFS (Progression-Free Survival)
Median PFS
Lenvatinib
Placebop<0.0001
18.3 months
3.6 months

N (%)

Lenvatinib(n = 261)

Placebo(n = 131)ORR

169 (65%)

2 (2%)

59.0–70.5

0.0–3.6(Objective Response Rate)

95% CI(Confidence Interval)

p-value

Lenvatinib
placebo

CR (Complete Response)

4 (2%)0

PR (Partial Response)

165
(63%)

2 (2%)≥ at 23 weeks

40 (15%)39 (30%)PD (Progressive Disease)18 (7%)

52 (40%)Median responsetime (months)(95% CI)

2.0(1.9–3.5)–

SD (Stable Disease)

Lenvatinib treatment arm demonstrated astatistically significant prolongation in PFS
Hazard ratio: 0.21 (99% CI= 0.14-0.31, p<0.0001)
Oral presentation held at ASCO
12*

* ASCO: Annual Meeting of the American Society of Clinical Oncology in 2014

<0.0001

Both arms did not reach median OS
Majority (83%) patients in the placebo arm
crossed over to receive Lenvatinib
Most common adverse events
Hypertension (67.8%), diarrhea (59.4%), decreased
appetite (50.2%), weight loss (46.4%), vomiting (41.0%)

Grade 3 or higher adverse events
Hypertension (41.8%), proteinuria (10.0%), weight loss
(9.6%), diarrhea (8.0%), decreased appetite (5.4%)

Investigational Lenvatinib

Thyroid cancer: Japan submission achieved in June

Thyroid cancer
Based on favorable results of phase III study(SELECT Study)First submission in the world wasachieved in Japan in June
Plan to submit
in the U.S. and EU in August)
Granted Orphan Drug Designation
for thyroid cancer in Japan, U.S. and EU

In-house developed
selective tyrosine kinase
inhibitor with a uniquebinding mode
Selectively inhibits
the kinase activities of
5 RTKs*
)

PDGFR

VEGFR

RET

Global approval anticipated in
FY2014 - FY2015
13* receptor tyrosine kinase

FGFR

KIT

Investigational Lenvatinib

Continue investment in other tumor types
to accelerate development
Thyroid cancer

Hepatocellular carcinoma(HCC)

Proactive investment toaccelerate development

Submitted in Japan
Plan to submit in
U.S. and Europe inAugustPhase III study (Study 304) ongoing
HCC

Investigational lenvatinib vs sorafenib
Primary endpoint: OS

Plan to submit
in FY2016

Secondary endpoint: PFS
Favorable data obtained
from phase II study

Endometrial
cancerPlan to submit in FY2016
Non-small cell lung cancer (NSCLC)

Submission
Phase III

NSCLC

Rapid progression in patient enrollment:
LPI*1 anticipated in FY2014

Phase II)
Two phase II studies are ongoing Study 703: phase II study of monotherapy
NSCLC patients receiving
3rd or later line therapy
Lenvatinib + BSC*2
vsPlacebo +BSC
Primary endpoint: OSPFSOSLenvatinib + BSC

Lenvatinib + BSC

Placebo + BSC

Data from the study presented
at ASCO*3

Placebo + BSC

 Study 209: phase II study in patients with RET-translocation
14 *1: LPI: Last Patient In *2: Best Supportive Care *3: ASCO: Annual Meeting of the American Society of Clinical Oncology in 2014

Halaven

Received approval for earlier line treatment for MBC in EU
Metastatic Breast Cancer(MBC) Important efficacy data from a pooled analysis of over 1,800
subjects with all subtypes of MBC was presented at ASCO*1
Data from a pooled analysis of Studies 305 and 301
Overall

HER2 positive

HER2 negative

Triple negative

eribulin

control*2

eribulin

control*2

eribulin

control*2

eribulin

control*2

N

1062

802

169

123

748

572

243

185

Median OS (months)*3

15.2

12.8

13.5

12.2

15.2

12.3

12.9

8.2

HR (95% CI)*40.85(0.77, 0.95)

0.82(0.62, 1.06)

0.82(0.72, 0.93)

0.74(0.60, 0.92)

0.003

0.135

0.002

0.006

p - value *4⇒

Significantly prolonged OS (overall survival) in patients with certain subgroups of MBC

 Earlier line treatment (EU): Received approval in June 2014
 HER2 negative breast cancer 1st /2nd lines (U.S.): phase III study with ACCRU*5 network is ongoing Neoadjuvant therapy for triple-negative breast cancer: preparing for phase III study

Non-small cell lung cancer and soft tissue sarcoma*6

Phase III study ongoing*1: ASCO: Annual Meeting of the American Society of Clinical Oncology in 2014 *2: Physicians’ choice or capecitabine *3: Based on survival curve adjusted by study

15 *4: Stratified by geographic region, prior capecitabine use and study (plus HER2 status for overall group only; plus triple negative for HER2 negative group only)*5: ACCRU：The Academic and Community Cancer Research United *6: Investigational use

Fycompa

In-house developed first-in-class non-competitive
AMPA receptor antagonist
Primary generalized tonic-clonic seizures (PGTC)*1
Met the primary endpoint in phase III study (Study 332)
Primary endpoint for U.S. submission
Percentage change in seizure
frequency

Primary endpoint for EU submission
50% PGTC responder rate
(Percentage of patients achieving > 50% reduction in seizure frequency)

U.S. and EU: plan to submit in 2Q FY2014
Japan: Plan to submit in conjunction with indication for partial-onset seizures in FY2015

Seeking to provide benefit to patients with partial-onset
seizures and potentially to patients with PGTC, which
account for approx. 60% and 20% of the estimated 5.7
million epilepsy patient, respectively, in the U.S.,
Europe and Japan.

Others4%
Generalized
seizuresexcluding PGTC:
16%

PGTC
23%

Source: Hauser WA, et al. Epilepsia

partial-onset
seizures:57%*2

Providing benefit toapprox. 80% of all epilepsy
patients*3

Partial-onset seizures:
Obtained approval in 39 countries and under approval review in 16 countries
Japan and Asian: phase III study (Study 335) is ongoing (Achieved LPI*4 in March 2014)16 *1: Investigational use *2: Source: Decision Resources*3: Potential percentage of patients for adjunctive therapy for partial-onset seizures and PGTC. Fycompa is currently
approved as an adjunctive therapy for partial-onset seizures (with or without secondary generalized seizures) in patients with epilepsy. *4: LPI: Last Patient In

Product Pipeline To Support Sustainable Growth
Strategic investments along withinvestigational Lenvatinib, Halaven and Fycompa

Investigational An in-house developed orexin receptor antagonist
E2006
Potential sleep inducer to induce natural sleep
Outline of phase II study Insomnia
 Study with adaptive design

Obtained favorable results on primary endpointfrom phase II study (a dose-response study)
Plan to initiate phase III study in 4Q FY2014
subject to consultation with agencies

Next-generation AD treatments to slow
the progression of disease
A novel monoclonal antibody
designed to remove Amyloidbeta protofibrils

Phase II study with adaptive design
ongoing⇒ Topline results anticipated in FY2015
Investigational
E2609

In-house developed Betasecretase (BACE) inhibitor

Plan to initiate phase II study
in 3Q FY2014
17 * Investigational use

15-day administration at 6 different doses

 Primary endpoint:
Sleep Efficiency (SE)Next-day residual sleepiness (KSS)
SE: time asleep / total time in bed
KSS: Karolinska sleepiness scale: a scale for evaluating
subjective sleepiness

Investigational
Avatrombopag

Joint development with Biogen Idec Inc.
Investigational
BAN2401

Thrombopoietin receptor agonist
seeking status of potential
first-in-classThrombocytopenia with chronic liver disease patients who will
undergo elective surgical procedures

Phase III studies ongoing

Plan to submit in FY2015

BELVIQ® Selective 5-HT receptor agonist
2c Obesity (Japan): Initiated phase I study Smoking cessation*: Phase II study ongoing Cardiovascular Outcomes Trial (CVOT): Initiated in
January 2014
 Phentermine co-administration*: Pilot safety study ongoing Once-daily formulation: Completed initial PK study

FY2014 Goals
Proactive investment in three areas to return to growth trajectory
Simultaneous multi-brand expansion
4 global brands*1 + Regional brands

Proactive investments and steady progressin major R&D projects

Rapid expansion and strengthening businessin Asia and strategic markets*2

Return to growth trajectory in terms of revenue and profit
in FY2015 beyond
18*1: Halaven, Fycompa, BELVIQ® and investigational lenvatinib*2: Canada, Mexico, Brazil, Russia, Middle East and Australia

Reference Data

19

Revenue by Reporting Segment(Billion yen, %)April – June 2013

Results

Japan*1

81.1%

April – June 2014

Results

53.0

73.7

%

55.5

Americas*2

41.3

27.0

25.4

19.1

Asia*3

13.4

8.7

16.3

12.3

EMEA*4

7.7

5.0

8.8

6.7

Consumer
Healthcare (Japan)*5

4.2

2.7

3.8

2.8

YoY

91

53%

62
[60]
122
[119]
115
[106]

96.6

128.0

96.4

87

Others

5.3

3.4

4.8

3.6

92

132.8

100.0

87

[ ] based on local currency

19%

Consumer
Healthcare(Japan)
and others

10%

5%
6%

7%
6%

7%

1Q FY2013

1Q FY2014

Plan“Hayabusa”
FY20157%

Pharmaceutical businesses of Japan, Americas, Asia, and EMEA

20

Americas

24%

12%

9%
152.8 100.0

52%

EMEA

27%
147.6

55%

Asia

90

Reportingsegment Total

Consolidated
revenueJapan*1: Prescription medicines, generics and diagnostics*2: North, Central, and South America*3: China, South Korea, Taiwan, India, and ASEAN *4: Europe, Middle East, Africa, Russia, and Oceania*5: Over-the-counter products (OTC)Profit by Reporting Segment(Billion yen, %)April – June 2013
Results% ofrevenue%

Results% ofrevenue%

YoY

Japan*1

42.9

73.3

52.9

33.7

83.5

45.7

78

Americas*2

8.7

14.9

21.1

0.1

0.2

0.3

1
[1]

Asia*3

3.0

5.2

22.7

4.3

10.7

26.4

142
[138]

EMEA*4

0.7

1.3

9.7

1.1

2.7

12.2

144
[125]

Consumer Healthcare(Japan)*5

0.5

0.9

12.0

(0.2)

Reporting segment
Total

55.9

95.5

37.9

39.0

96.7

30.5

70

2.6

4.5

50.3

1.3

3.3

27.4

50

OthersR&D expenses & Group
headquarters' management
costs and other expenses(40.0)

Consolidated Operating
Profit18.6

Pharmaceutical businesses of Japan, Americas, Asia, and EMEA

21

April – June 2014

*1: Prescription medicines, generics, and diagnostics*4: Europe, Middle East, Africa, Russia, and Oceania(31.8)
12.1

80

8.5

6.4

46

[ ] based on local currency*2: North, Central, and South America *3: China, South Korea, Taiwan, India, and ASEAN*5: Over-the-counter products (OTC)Performance of Japan Pharmaceuticals Business(Billion yen, %)April – June 2013
Results

22

April – June 2014%

Results%

YoY

Revenue

81.1

100.0

73.7

100.0

91

Prescription medicines

73.9

91.1

66.0

89.5

89

Aricept

18.3

22.6

13.4

18.2

73

Pariet

12.8

15.8

10.8

14.6

84

HUMIRA

6.9

8.5

7.8

10.5

112

Methycobal

6.7

8.2

6.3

8.6

94

Lyrica*

4.1

5.1

4.3

5.8

104

Warfarin

2.6

3.2

2.4

3.3

95

Actonel

2.2

2.7

1.9

2.5

86

Halaven

1.6

2.0

1.6

2.1

96

Selbex

1.8

2.3

1.4

1.9

76

Lunesta

0.6

0.7

1.0

1.4

176

Generics

5.8

7.1

6.4

8.6

110

Diagnostics

1.4

1.7

1.4

1.9

98

Segment profit

42.9

52.9

33.7

45.7

78

*: Alliance revenue

Performance of Americas Pharmaceuticals Business(Billion yen, %)April – June 2013
Results%

April – June 2014
Results%

YoY

Revenue

41.3

100.0

25.4

100.0

62

[60]

Aloxi

10.3

25.0

12.6

49.5

122

[118]

AcipHex

15.5

37.5

3.9

15.2

25

[24]

Halaven

3.3

7.9

3.8

15.0

117

[113]

Banzel

1.5

3.7

2.2

8.8

145

[141]

BELVIQ®

0.4

1.0

1.0

4.0

250

[241]

Fycompa

0

0.0

0.2

0.6

1548

[1511]

Segment Profit

8.7

21.1

0.1

0.3

1

[1]

[ ] based on local currency

23Performance of Asia Pharmaceuticals Business(Billion yen, %)<Asia>
April – June 2013

Results
Revenue
Methycobal
Aricept
HUMIRA
ParietStronger Neo-Minophagen C/
Glycyron Tablets
HalavenSegment Profit%

April – June 2014

Results

%

YoY

13.4
3.6
2.9
1.6
1.4

100.0
26.8
22.0
12.1
10.7

16.3
4.6
3.2
2.0
1.5

100.0
28.3
19.8
12.1
9.5

122
129
110
122
108

[119]
[127]
[104]
[114]
[107]

1.2

9.0

1.3

8.2

111

[108]

0.1
3.0

0.5
22.7

0.2
4.3

1.3
26.4

347
142

[344]
[138]

[ ] based on local currency<China>(MM RMB, %)April – June 2013
Results
Revenue
Methycobal
Stronger Neo-Minophagen C/
Glycyron Tablets
Aricept
Pariet24%

April – June 2014
Results

%

YoY

438
188

100.0
42.8

559
245

100.0
43.9

127
131

74

16.9

80

14.4

109

62
34

14.1
7.7

67
43

11.9
7.7

108
127

Performance of EMEA and Consumer Healthcare(Mainly OTC and other businesses)＜EMEA*＞(Billion yen, %)April – June 2013
Results%

April – June 2014
Results%

YoY

Revenue

7.7

100.0

8.8

100.0

115

[106]

Halaven

2.0

26.0

2.6

29.2

129

[119]

Zonegran

1.5

20.0

1.9

22.0

127

[116]

Zebinix

0.5

7.0

0.7

7.8

128

[117]

Fycompa

0.6

7.4

0.5

6.1

96

[87]

Inovelon

0.5

6.0

0.5

6.1

117

[107]

Segment Profit

0.7

9.7

1.1

12.2

144

[125]

[ ] based on local currency* Europe, Middle East, Africa, Russia, and Oceania＜Consumer Healthcare - Japan＞(Billion yen, %)April – June 2013
Results

25%

April – June 2014
Results%

YoY

Revenue

4.2

100.0

3.8

100.0

90

Chocola BB Group

2.9

68.3

2.5

66.3

87

Segment Profit

0.5

12.0

(0.2)

FY2013 1Q Consolidated Financial Results
Impact of IFRS Introduction(Billion yen)

Revenue

Japan GAAP
Adjustment of sales incentives from
SG&A to deduction of revenue

154.2

Cost of
R&D
sales expenses

46.3

39.6

-0.5

Amortization of intangibles (In-licensing
products) capitalized under IFRS

SG&A
expenses

54.2

Nonoperating
Other
Operating income /income /profitexpenses,
expensesSpecialgain / loss

-

-0.5

-2.2
-2.3

Non-amortization of goodwill-0.7

Incometaxes

Profit fortheperiod

-

4.0

9.4

-

0.2

Capitalization upfront/milestone
payments for in-licensing products

14.2

Financialincome /
costs

-

-0.2

-0.1

-0.1

2.2

0.8

1.4

2.3

2.3

Reclassification of foreign exchange
losses

-0.3

-0.3

0.3

-

Reclassification of gain on sales of noncurrent assets

0.2

0.2

-0.2

-

Interest and dividend income / Interest
expenses

-

1.0

-1.0

Reclassification of gain on investment
securities (special gain)

-

-0.4

0.1

-0.1

-0.2

0.3
4.4
18.6

0.0
0.7
-

-0.1
-0.9
-0.9

0.7
1.3
5.3

-0.5
2.9
12.3

Other
Total adjustments

IFRS

26

-0.9
-1.4
152.8

-0.3
-0.1
46.2

-0.2
-2.4
37.3

-0.8
-3.6
50.6

-0.0
-0.2
-0.2

-